Varian Medical Systems Inc

Varian Medical Systems — Q3 FY2019 Earnings Presentation

33 slides from Varian Medical Systems's earnings presentation, Jul 24, 2019

  1. Slide 1: Third Quarter Fiscal Year 2019

    Third Quarter Fiscal Year 2019 July 24, 2019 J. Michael Bruff Senior Vice President, Investor Relations [email protected]

  2. Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S

  3. Slide 3: Agenda Q3 FY 2019 earnings

    Agenda Q3 FY 2019 earnings 1. Third Quarter Results 2. Total Company Performance 3. Segment Performance 4. FY 2019 Guidance 5. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

  4. Slide 4: Q3 FY 2019 key financial metrics

    Q3 FY 2019 key financial metrics $M Q3 Y/Y Oncology Orders1 $778 2% • Delivered exceptional performance growing Non-GAAP operating earnings faster than Revenues $826 16% revenue Oncology $793 19% Proton Solutions $31 (26%) • US/China tariffs negatively impacted revenue growth by $10 million or 140 b

  5. Slide 5: Long-term growth and value creation strategy

    Long-term growth and value creation strategy Global Leader Global Leader in Multi-Disciplinary, in Radiation Therapy Integrated Cancer Care Solutions Interventional Surgical oncology oncology Radiation Radiosurgery oncology OIS Call on all Aggregate oncologists data Radiation oncology Radiation Radi

  6. Slide 6: How we plan to achieve our strategy

    How we plan to achieve our strategy We Are Here Long-Term Growth and Where We Are Headed Global Leader in Value Creation Strategy Global Leader in Multi- Radiation Therapy Disciplinary, Integrated Cancer Care Solutions Growth Priorities Interventional Surgical oncology oncology Radiation Radiosurger

  7. Slide 7: Executing on long-term growth strategy

    Executing on long-term growth strategy Strengthen Leadership Extend Expand in Radiation Therapy Global Footprint Addressable Market KEY METRICS KEY METRICS KEY METRICS • Global market leader • 8th consecutive quarter of double-digit • Software revenues grew +24% with >55% share in radiation therapy;

  8. Slide 8: Key wins

    Key wins Americas EMEA APAC U.S. Government – National Cancer Care India – Tata Trusts Uzbekistan VA Medical Alliance 6 TrueBeam systems 2 linear accelerators and 2 4 Halcyons, 3 TrueBeams, 6 TrueBeam systems brachytherapy systems 1 SRS, and 2 Bravos China Australia 5 Halcyon systems 3 TrueBeam syst

  9. Slide 9: Varian linac net installed base

    Varian linac net installed base Installed base growth 8,412 Varian strengthened its global leadership in radiation therapy • Net installed base grew +5% or 366 units, driving future recurring software and services revenues +366 (+5%) • All three geographies grew respective installed base in the thir

  10. Slide 10: Total Company Performance

    Total Company Performance varian

  11. Slide 11: Total company results (GAAP)

    Total company results (GAAP) Key P&L financial metrics • Gross Orders grew double digits due to three new proton orders taken in the quarter totalling $108 VARIAN million $M Q3 FY19 Y/Y TTM Y/Y • Revenue growth driven by strong hardware and Gross Orders $892 16% $3,457 11% software performance in th

  12. Slide 12: Total company results (non-GAAP)

    Total company results (non-GAAP) Key P&L financial metrics VARIAN • Gross Orders grew double digits due to three new proton orders taken in the quarter totalling $108 $M Q3 FY19 Y/Y TTM Y/Y million Gross Orders $892 16% $3,457 11% Revenues $826 16% $3,148 11% • Revenue growth driven by strong hardwa

  13. Slide 13: Total company results: balance sheet and cash flow metrics

    Total company results Key balance sheet and cash flow metrics Cash & Cash Equivalents ($M) Total Debt ($M) -2% Y/Y +383M Y/Y $700 $500 • Cash & Cash Equivalents of $523 million $400 • Total Debt of $401 million from borrowings $600 $300 related to the acquisition of CTSI, Endocare, and $200 Alicon $

  14. Slide 14: Capital allocation priorities

    Capital allocation priorities Q3 update Long-term value creation strategy that includes balancing growth, profitability and liquidity Organic • Investments in FLASH technology, software capability, key programs such as adaptive radiotherapy, and R&D and Capital infrastructure Investments Inorganic •

  15. Slide 15: Segment Performance

    Segment Performance varian

  16. Slide 16: Oncology Systems segment (GAAP)

    Oncology Systems segment (GAAP) Key financial metrics VARIAN • Gross Orders up +2% or +4% in constant $M Q3 FY19 Y/Y TTM Y/Y currency, and +11% over the trailing twelve Gross Orders $778 2% $3,328 11% months, or +13% in constant currency Revenues $793 19% $2,998 12% • Product Revenue growth driven b

  17. Slide 17: Oncology Systems gross orders by geography

    Oncology Systems gross orders by geography APAC AMERICAS -1% Q3 Y/Y -1% Q3 Y/Y1 (+1% cc) (-1% cc) 22% TTM Y/Y 6% TTM Y/Y1 (+24% cc) (+6% cc) (1) In North America, Q3 orders growth of -1% and TTM orders growth of 6% EMEA 8% Q3 Y/Y (+13% cc) 13% TTM Y/Y 17 (+17% cc)

  18. Slide 18: Proton Solutions segment (GAAP)

    Proton Solutions segment (GAAP) Key financial metrics • Gross Orders increased due to three new orders taken in the quarter totalling $108 million VARIAN • Product Revenues driven by the progress made in $M Q3 FY19 Y/Y TTM Y/Y centers under construction Gross Orders $111 2,866% $127 1% • Services Re

  19. Slide 19: ProBeam proton therapy system sites

    ProBeam proton therapy system sites 26 79 ProBeam Total Sites Rooms 11 35 Operational Operational Operational Centers Centers Under Development Sites Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 19

  20. Slide 20: FY 2019 Guidance

    FY 2019 Guidance varian

  21. Slide 21: Updated guidance for fiscal year 2019

    Varian consolidated Updated guidance for fiscal year 2019 • Guidance considers projected market growth and continued momentum of Varian’s portfolio • Updated guidance considers the following impacts VARIAN to operating earnings: $M Prior Guidance Updated Guidance1 − $5 million positive impact due to

  22. Slide 22: In summary, we are…

    In summary, we are… Growing our net installed base Extending our global footprint and market-leading, best-in-class …Driving product portfolio toward our vision Becoming a global leader in multi-disciplinary, integrated cancer care solutions of a world without fear of cancer Delivering on our long-t

  23. Slide 23: Appendix

    Appendix

  24. Slide 24: Non-GAAP disclosure

    Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. We define

  25. Slide 25: GAAP to non-GAAP reconciliation

    GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES Dollars and shares in millions, except per share amounts 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) $4.1 $4.8 $4.2 $6.1 $6

  26. Slide 26: Total revenues by sales classification

    Total revenues by sales classification $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Product revenues 365.0 445.5 400.2 430.5 461.3 Y/Y 14% 11% 9% 9% 26% Service revenues 344.1 356.1 340.8 348.9 364.5 Y/Y 10% 11% 9% 4% 6% Total revenues 709.1 801.6 741.0 779.4 825.8 Y/Y 12% 11% 9% 7% 16% Y/Y – CC 10% 1

  27. Slide 27: Total revenues by product type

    Total revenues by product type $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 3Q Y/Y Hardware $314.6 $389.9 $347.2 $367.0 $387.9 23% Oncology Systems $276.5 $350.3 $313.6 $339.1 $361.7 31% Proton Solutions $38.1 $39.6 $33.6 $27.9 $24.2 -36% Other $2.0 —% Software1 $125.1 $132.3 $131.2 $144.2 $155.7 24%

  28. Slide 28: Total revenues by region

    Total revenues by region $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Americas revenues $342.6 $397.4 $350.4 $371.3 $401.2 Y/Y 2% 8% -2% 9% 17% Y/Y – CC 2% 8% -2% 10% 17% EMEA revenues $229.7 $266.3 $251.0 $261.5 $271.3 Y/Y 35% 21% 30% 3% 18% Y/Y – CC 28% 22% 33% 10% 24% APAC revenues $136.8 $137.9 $1

  29. Slide 29: Total Oncology Systems revenues by sales classification

    Total Oncology Systems revenues by sales classification $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Product revenues $326.9 $402.1 $366.6 $402.6 $433.8 Y/Y 29% 15% 8% 11% 33% Y/Y – CC 26% 15% 9% 14% 36% Service revenues $340.3 $353.5 $335.9 $344.2 $359.1 Y/Y 10% 11% 8% 3% 6% Y/Y – CC 7% 12% 9% 6% 8%

  30. Slide 30: Total Oncology Systems revenues by region

    Total Oncology Systems revenues by region $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Americas revenues $323.2 $369.5 $330.8 $357.1 $385.6 Y/Y 13% 6% -2% 11% 19% Y/Y – CC 13% 7% -2% 12% 20% EMEA revenues $208.5 $250.0 $234.5 $245.3 $256.4 Y/Y 32% 27% 28% 2% 23% Y/Y – CC 24% 28% 31% 9% 30% APAC revenu

  31. Slide 31: Total Proton Solutions revenues by sales classification

    Total Proton Solutions revenues by sales classification $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Product revenues $38.1 $43.4 $33.6 $27.9 $25.5 Y/Y -43% -12% 23% -7% -33% Service revenues $3.8 $2.6 $4.9 $4.7 $5.4 Y/Y 95% -23% 172% 151% 44% Total revenues $41.9 $46.0 $38.5 $32.6 $30.9 Y/Y -39% -12%

  32. Slide 32: Oncology Systems gross orders by region

    Oncology Systems gross orders by region $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Americas orders $362.9 $505.7 $335.9 $366.1 $357.4 Y/Y 9% 6% 12% 7% -1% Y/Y – CC 9% 6% 12% 8% -1% EMEA orders $259.1 $360.8 $218.3 $233.3 $281.1 Y/Y 27% 14% 15% 17% 8% Y/Y – CC 21% 15% 17% 25% 13% APAC orders $141.3 $

  33. Slide 33: Our promise: People powering victories

    Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W

Varian Medical Systems — Q3 FY2019 Earnings Presentation on 6ix